WebMar 24, 2024 · For more information about the trial, please visit Clinicaltrials.gov. Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. WebIMFINZI is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not …

AZ takes aim at BMS

WebInsert either your Aegean Booking Reference, a 6-character code located on your booking confirmation email, or the Touroperator Booking Reference received from your travel agent. Last name Online Check-in is available … WebJun 30, 2024 · AEGEAN. AEGEAN is a randomised, double-blind, multi-centre, global Phase III trial evaluating Imfinzi as perioperative treatment for patients with resectable Stage IIA-IIIB (tumours greater than or equal to 4cm or node positive) NSCLC with no EGFR or ALK genomic tumour aberrations, irrespective of PD-L1 expression. Perioperative … hb s45c

AstraZeneca advances its pipeline and highlights progress in …

WebMar 9, 2024 · AEGEAN is a randomized, double-blind, multi-center, placebo-controlled global Phase III trial evaluating IMFINZI as perioperative treatment for patients with … WebMar 9, 2024 · WILMINGTON, Del., (BUSINESS WIRE) -- Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed... WebAug 9, 2024 · IMFINZI is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer (ES-SCLC) based on the CASPIAN Phase III trial. In 2024, updated results from the CASPIAN trial showed IMFINZI plus chemotherapy tripled patient survival at three years versus … hbs500